Who Paid My Doc
Jennifer Rose-Nussbaumer
Cornea and External Diseases Specialist Stanford, CA Medical Doctor
NPI 1598912859 CMS profile 1297225
300 Pasteur Dr, Stanford, CA 94305
General payments
$1,639
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jennifer Rose-Nussbaumer of Stanford, CA is reported in the CMS Open Payments database as having received $1,639 across 21 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 47th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $339 | 4 | |
| 2024 | General | $329 | 8 | |
| 2023 | General | $499 | 4 | |
| 2022 | General | $171 | 2 | |
| 2021 | General | $224 | 2 | |
| 2019 | General | $77 | 1 |
Beside peers
- Jennifer Rose-Nussbaumer
- Cornea and External Diseases Specialist median
- Middle half of Cornea and External Diseases Specialist
- National median
In program year 2025, general payments to Jennifer Rose-Nussbaumer were reported at $339. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.
Show as a table
| Year | Jennifer Rose-Nussbaumer | Cornea and External Diseases Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $77 | $276 | $111–$734 | $163 |
| 2020 | $0 | $146 | $48–$330 | $114 |
| 2021 | $224 | $254 | $116–$566 | $132 |
| 2022 | $171 | $251 | $106–$729 | $149 |
| 2023 | $499 | $344 | $149–$759 | $160 |
| 2024 | $329 | $366 | $170–$927 | $164 |
| 2025 | $339 | $477 | $193–$1,174 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
514
Drug cost
$44,230
Branded share of claims
41.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Restasis Cyclosporine | Brand | 13 | $9,188 | |
| Xiidra Lifitegrast | Brand | 11 | $7,577 | |
| Prednisolone Acetate | Generic | 134 | $7,427 | |
| Valacyclovir Valacyclovir Hcl | Brand | 51 | $5,035 | |
| Cyclosporine | Generic | 19 | $4,003 | |
| Rhopressa Netarsudil Mesylate | Brand | 12 | $3,396 | |
| Dexamethasone Sodium Phosphate | Generic | 80 | $3,138 | |
| Fluorometholone | Generic | 19 | $1,725 | |
| Moxifloxacin Moxifloxacin Hcl | Brand | 48 | $1,180 | |
| Polymyxin B Sul-Trimethoprim Polymyxin B Sulf/Trimethoprim | Brand | 60 | $477 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 43 billing codesPaid by Medicare
$95,401
Medicare patients
263
Services billed
960
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 65% | |
| Arthritis | 41% | |
| Diabetes | 28% | |
| Ischemic heart disease | 23% | |
| Osteoporosis | 19% | |
| Chronic kidney disease | 18% | |
| Depression | 18% | |
| Atrial fibrillation | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
21 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cornea and External Diseases Specialist in California
Sumit Garg
Cornea and External Diseases Specialist · Irvine, CA
Jillian Chong
Cornea and External Diseases Specialist · Beverly Hills, CA
Tyson Kim
Cornea and External Diseases Specialist · San Francisco, CA
Edward Manche
Cornea and External Diseases Specialist · Stanford, CA
Michael Savetsky
Cornea and External Diseases Specialist · Culver City, CA
Michael Saidel
Cornea and External Diseases Specialist · Sonoma, CA
Related records
Cornea and External Diseases Specialist in California
Practitioners in the same specialty and state, ranked by reported value.
All Cornea and External Diseases Specialist
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.